Literature DB >> 7759157

Selective inhibition of spontaneous pulmonary metastasis of Lewis lung carcinoma by 5'-deoxy-5-fluorouridine.

T Ishikawa1, M Ura, T Yamamoto, Y Tanaka, H Ishitsuka.   

Abstract

5'-deoxy-5-fluorouridine (5'-FUdR) is a cytostatic that is biotransformed to 5-fluorouracil (5-FUra) by pyrimidine nucleoside phosphorylase (PyNPase), the expression of which is up-regulated by tumor necrosis factor alpha (TNF alpha), interleukin-1 alpha (IL-1 alpha) and interferon gamma (IFN gamma). In Lewis lung carcinoma (LLC) cell cultures, these inflammatory cytokines up-regulated the expression of type-IV collagenase, metastatic factor, as well as PyNPase and consequently enhanced the antiproliferative activity of 5'-FUdR. However, the activity of 5-FUra was not enhanced. It appears that 5'-FUdR selectively kills highly metastatic cells which are exposed to these intrinsic cytokines in tumor tissues, because of their high PyNPase activity. In fact, 5'-FUdR inhibited the spontaneous metastasis of LLC from the s.c. inoculation site to the lung. When 5'-FUdR was given during the process of metastasis it greatly reduced the number of tumor nodules in the lung even at doses 46 times lower than those inhibiting the primary tumor growth. In addition, 5'-FUdR, but not 5-FUra, lowered type-IV collagenase levels in the tumors at the low dose showing only anti-metastatic activity. On the other hand, 5-FUra showed anti-metastatic activity at doses similar to or only several times lower than those inhibiting the primary tumor growth.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7759157     DOI: 10.1002/ijc.2910610415

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

Review 1.  Capecitabine.

Authors:  D R Budman
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

Review 2.  Capecitabine: preclinical pharmacology studies.

Authors:  H Ishitsuka
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

3.  Effects of sex steroids and growth factors on invasive activity and 5'-deoxy-5-fluorouridine sensitivity in ovarian adenocarcinoma OMC-3 cells.

Authors:  M Ueda; H Fujii; K Yoshizawa; K Kumagai; K Ueki; Y Terai; T Yanagihara; M Ueki
Journal:  Jpn J Cancer Res       Date:  1998-12

4.  Regulation of dihydropyrimidine dehydrogenase and pyrimidine nucleoside phosphorylase activities by growth factors and subsequent effects on 5-fluorouracil sensitivity in tumor cells.

Authors:  M Ueda; K Kitaura; O Kusada; Y Mochizuki; N Yamada; Y Terai; K Kumagai; K Ueki; M Ueki
Journal:  Jpn J Cancer Res       Date:  2000-11

5.  Antitumor effects of 5'-deoxy-5-fluorouridine in combination with recombinant human interleukin 2 on murine colon carcinoma 26.

Authors:  K Midoro; K Gotoh; T Houkan; K Yukishige; K Fujiwara; K Ootsu
Journal:  Jpn J Cancer Res       Date:  1997-03

6.  The potential for oral combination chemotherapy of 5'-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer.

Authors:  M Yoshimoto; K Tada; N Tokudome; G Kutomi; M Tanabe; T Goto; S Nishimura; M Makita; F Kasumi
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.